What type of study is this?

December 8, 2025BloodOpen Access

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

View Full Paper

Ask AI

Bookmark

Rates of complete response were similar between ICV and IC regimens with 79% for ICV and 69% for IC.
Febrile neutropenia occurred in 89% of the cohort, showing no significant differences between treatment groups.
Salvage treatment led to significant improvements in overall survival for all patients undergoing HCT post-treatment.
Substituting etoposide for anthracycline showed no impact on response rates or overall survival outcomes.

No takes yet. Share an insight, caveat, or question.

Retrospective analysis reveals comparable response rates in relapsed AML patients, indicating potential for venetoclax integration.

Ngo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark